دورية أكاديمية
أعرض في EDS

Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
المؤلفون: Naranjo NM; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Kennedy A; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Testa A; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Verrillo CE; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Altieri AD; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Kean R; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Hooper DC; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA., Yu J; Department of Urology, Emory University School of Medicine, Atlanta, GA, USA., Zhao J; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA., Abinader O; Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Pickles MW; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Hawkins A; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Kelly WK; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Mitra R; Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Languino LR; Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA.
المصدر: Cancer biology & therapy [Cancer Biol Ther] 2024 Dec 31; Vol. 25 (1), pp. 2364433. Date of Electronic Publication: 2024 Jun 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Georgetown, TX : Landes Bioscience, c2002-
مواضيع طبية MeSH: Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism , Adenocarcinoma*/genetics , Adenocarcinoma*/pathology , Adenocarcinoma*/metabolism, Humans ; Male ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Gene Expression Regulation, Neoplastic ; Synaptophysin/metabolism ; Synaptophysin/genetics ; Extracellular Vesicles/metabolism ; Extracellular Vesicles/genetics ; Gene Expression Profiling/methods
مستخلص: Prostate cancer has heterogeneous growth patterns, and its prognosis is the poorest when it progresses to a neuroendocrine phenotype. Using bioinformatic analysis, we evaluated RNA expression of neuroendocrine genes in a panel of five different cancer types: prostate adenocarcinoma, breast cancer, kidney chromophobe, kidney renal clear cell carcinoma and kidney renal papillary cell carcinoma. Our results show that specific neuroendocrine genes are significantly dysregulated in these tumors, suggesting that they play an active role in cancer progression. Among others, synaptophysin (SYP), a conventional neuroendocrine marker, is upregulated in prostate adenocarcinoma (PRAD) and breast cancer (BRCA). Our analysis shows that SYP is enriched in small extracellular vesicles (sEVs) derived from plasma of PRAD patients, but it is absent in sEVs derived from plasma of healthy donors. Similarly, classical sEV markers are enriched in sEVs derived from plasma of prostate cancer patients, but weakly detectable in sEVs derived from plasma of healthy donors. Overall, our results pave the way to explore new strategies to diagnose these diseases based on the neuroendocrine gene expression in patient tumors or plasma sEVs.
References: Cell Death Dis. 2022 Feb 8;13(2):122. (PMID: 35136055)
Nat Rev Cancer. 2020 Dec;20(12):697-709. (PMID: 32958932)
FASEB J. 2016 Dec;30(12):4141-4148. (PMID: 27601437)
J Extracell Vesicles. 2024 Feb;13(2):e12404. (PMID: 38326288)
Nat Rev Urol. 2021 Feb;18(2):79-92. (PMID: 33328650)
Eur J Cancer. 2012 Mar;48(5):662-71. (PMID: 21945100)
Histopathology. 2012 Jan;60(1):87-117. (PMID: 22212080)
Clin Cancer Res. 2019 Jan 1;25(1):266-276. (PMID: 30287549)
Matrix Biol. 2019 Apr;77:41-57. (PMID: 30098419)
J Extracell Biol. 2023 Sep;2(9):e108. (PMID: 38046436)
Curr Urol Rep. 2016 Mar;17(3):25. (PMID: 26874537)
Biochem J. 2021 Nov 12;478(21):3905-3921. (PMID: 34622927)
Diagnostics (Basel). 2022 Jan 24;12(2):. (PMID: 35204378)
Front Oncol. 2021 May 05;11:628346. (PMID: 34026608)
Nat Rev Dis Primers. 2017 Mar 09;3:17009. (PMID: 28276433)
Cancer. 2017 Jan 1;123(2):200-209. (PMID: 27861752)
Asian J Urol. 2022 Jan;9(1):1-11. (PMID: 35198391)
Int J Mol Sci. 2020 Oct 14;21(20):. (PMID: 33066349)
J Extracell Vesicles. 2020 May 20;9(1):1763594. (PMID: 32595914)
Br J Cancer. 2008 Oct 21;99(8):1330-9. (PMID: 18827820)
J Pathol. 2022 Jul;257(4):466-478. (PMID: 35438189)
Matrix Biol. 2023 Dec;124:49-62. (PMID: 37956856)
Pathol Res Pract. 2018 Jun;214(6):848-856. (PMID: 29728311)
J Cell Biochem. 2017 Jan;118(1):66-73. (PMID: 27232975)
Front Oncol. 2022 Dec 13;12:963641. (PMID: 36582804)
N Engl J Med. 2014 Jul 31;371(5):424-33. (PMID: 24881730)
Science. 2020 Feb 7;367(6478):. (PMID: 32029601)
Cancers (Basel). 2020 Apr 02;12(4):. (PMID: 32252342)
J Extracell Vesicles. 2021 Feb;10(4):e12063. (PMID: 33613873)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Cells. 2022 Aug 10;11(16):. (PMID: 36010551)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Cancer Drug Resist. 2020;3:371-384. (PMID: 33062957)
Br J Cancer. 1991 May;63(5):715-8. (PMID: 1903950)
Clin Cancer Res. 2023 Aug 1;29(15):2933-2943. (PMID: 37223924)
Sci Rep. 2022 Nov 7;12(1):18879. (PMID: 36344556)
Cancer Discov. 2024 Mar 1;14(3):424-445. (PMID: 38197680)
Nat Med. 2016 Mar;22(3):298-305. (PMID: 26855148)
Curr Oncol Rep. 2021 Jan 12;23(2):15. (PMID: 33433737)
JAMA. 2019 Jan 22;321(3):288-300. (PMID: 30667505)
Ups J Med Sci. 1995;100(3):169-99. (PMID: 8808182)
Cancer Cell Int. 2011 Nov 18;11(1):41. (PMID: 22098917)
Nucleic Acids Res. 2016 May 5;44(8):e71. (PMID: 26704973)
Nat Cell Biol. 2019 Jan;21(1):9-17. (PMID: 30602770)
Cancer Cell. 2016 Apr 11;29(4):536-547. (PMID: 27050099)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Folia Biol (Praha). 2011;57(5):173-81. (PMID: 22123459)
Cell. 2020 Aug 20;182(4):1044-1061.e18. (PMID: 32795414)
Mol Cell Proteomics. 2015 Feb;14(2):263-76. (PMID: 25452312)
Biochem Biophys Res Commun. 2019 Mar 12;510(3):339-344. (PMID: 30722993)
Urol Oncol. 2021 Jun;39(6):327-337. (PMID: 34034966)
معلومات مُعتمدة: R01 CA255792 United States CA NCI NIH HHS; R01 CA217329 United States CA NCI NIH HHS; R01 CA224769 United States CA NCI NIH HHS; T32 CA236736 United States CA NCI NIH HHS; P30 CA056036 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Prostate cancer; exosomes; extracellular vesicles; neuroendocrine genes; patient plasma; synaptophysin
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Synaptophysin)
تواريخ الأحداث: Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240630
رمز التحديث: 20240630
مُعرف محوري في PubMed: PMC11212568
DOI: 10.1080/15384047.2024.2364433
PMID: 38926911
قاعدة البيانات: MEDLINE
الوصف
تدمد:1555-8576
DOI:10.1080/15384047.2024.2364433